BridgeMD
New treatment option for Androgenetic Alopecia
Official title Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients
ClinicalTrials.gov ID: NCT07429253
What this study is testing
What is Secretome?
Secretome is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for androgenetic alopecia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 25 to 59
You may be able to join if
- Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking...
- Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment...
- Female patients who are not currently pregnant or breastfeeding.
- Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
- Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
You likely can't join if
- Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
- Patients presenting with types of hair loss other than androgenetic alopecia.
- Patients currently undergoing therapy with 5-alpha reductase inhibitors.
- Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
- Patients with active infections and/or active dermatitis on the scalp.
- Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
See the full eligibility criteria
- Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof...
- Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr...
- Female patients who are not currently pregnant or breastfeeding.
- Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
- Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
- Patients who are proficient in Indonesian and willing to provide written informed consent.
- Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
- Patients presenting with types of hair loss other than androgenetic alopecia.
- Patients currently undergoing therapy with 5-alpha reductase inhibitors.
- Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
- Patients with active infections and/or active dermatitis on the scalp.
- Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
- History of hypertrophic scarring or blood clotting (coagulation) disorders.
- Patients unable to complete the research procedures in their entirety.
The study team makes the final eligibility decision.
Where it's taking place
- Denpasar, Bali, Indonesia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 25 years to 59 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Denpasar, Bali, Indonesia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.